CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare nerve disorder
Disease control CompletedThis study tested a new medicine called SAR445088 in 98 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that causes weakness and numbness in the arms and legs. The goal was to see if the drug can help control symptoms and reduce disability. Parti…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: PHASE2 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
Blood test may predict best dose for nerve disorder treatment
Knowledge-focused CompletedThis study looked at 20 adults with chronic nerve conditions (CIDP or MMN) who were starting IVIg treatment. Researchers wanted to see if changes in IgG levels in the blood after the first dose could help predict the best long-term dose for each patient. The goal is to make dosin…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Sponsor: Walton Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC